Search
Polysilicone-15
go.drugbank.com/drugs/DB11271ApprovedWhen included in various other cosmetic shampoos, conditioners, or hairsprays the compound also functions as an effective photostabilizer of the product [L2796, L2797, L2799, F87, F88, F89].
Camizestrant
go.drugbank.com/drugs/DB19218ApprovedInvestigational[L64094,L64107] The European Commission approved camizestrant on July 23, 2026, Health Canada authorized it on August 4, 2026, and the FDA granted accelerated approval on September 4, 2026. … [L64094,L64107] In pre- or peri-menopausal women and in men, camizestrant plus a CDK4/6 inhibitor is combined with an LHRH agonist or antagonist.
Remoxipride
go.drugbank.com/drugs/DB00409ApprovedWithdrawnRemoxipride is an atypical antipsychotic agent that is specific for dopamine D<sub>2</sub> receptors. … [A215422] It gained approval in the UK in 1989 but was withdrawn in 1993 after it was found to be associated with an increased incidence of aplastic anemia.[A215422,A215512]
Categories: Dopamine D2 Receptor AntagonistsInositol
go.drugbank.com/drugs/DB13178ApprovedInvestigationalWithdrawn[L1113] By the FDA, inositol is considered in the list of specific substances affirmed as generally recognized as safe (GRAS).[L2561] … [L2560] Inositol can be found as an ingredient of OTC products by Health Canada but all current product whose main ingredient is inositol are discontinued.
Mixtures: Dp 2000, Calcium Magnesium Plus Vitamin D LiquidFerumoxytol
go.drugbank.com/drugs/DB06215ApprovedInvestigationalFerumoxytol is an intravenously administered iron preparation previously indicated in the EU and the US for the treatment of iron deficiency anemia in adult patients with chronic kidney disease (CKD) [ … In January of 2015, the EMA withdrew marketing authorisation for Rienso (ferumoxytol) due to safety concerns.
Sotorasib
go.drugbank.com/drugs/DB15569ApprovedInvestigationalSotorasib, also known as AMG-510, is an acrylamide-derived KRAS inhibitor developed by Amgen. … [A187547] Sotorasib was granted FDA approval on May 28, 2021,[L34288] followed by the European Commission's approval on January 6, 2022.[L56070]
Synonyms: 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-(1M)-1-[4-methyl-2-(propan-2-yl)pyridin-3-yl]-4-[(2S)-2- methyl-4-(prop-2-enoyl)piperazin-1-yl]pyrido[2,3-d]pyrimidin-2(1H)-oneErgoloid mesylate
go.drugbank.com/drugs/DB01049Approved[L2639]Later in 1991, the mixture of ergoloid mesylates was retaken by Sun Pharmaceutical Industries and approved by the FDA. … Ergoloid Mesylate is an equiproportional preparation of three different ergotamantriones: dihydroergocornine, dihydroergocristine, and dihydroergocryptine.
Inclisiran
go.drugbank.com/drugs/DB14901ApprovedInvestigational[L28178] Inclisiran was later approved by the FDA on December 22, 2021, for the treatment of heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease in adults … [A225953,A225958] Lowering circulating plasma LDL-C levels offers an additional benefit of reducing the risk of cardiovascular disease (CVD) and improving cardiovascular outcomes, as hypercholesterolemia
Verteporfin
go.drugbank.com/drugs/DB00460ApprovedInvestigationalVerteporfin, marketed as Visudyne, is a benzoporphyrin derivative comprising a 50:50 mixture of two isomers: CL-315555 and CL-315585. It is used as a photosensitizer in photodynamic therapy to eliminate abnormal blood vessels in wet form...
Dapagliflozin
go.drugbank.com/drugs/DB06292ApprovedInvestigational[A261601] Dapagliflozin was originally approved by the FDA on Jan 08, 2014, to improve glycemic control in adults with type 2 diabetes in conjunction with diet and exercise. … [A6757] Dapagliflozin has been investigated either as monotherapy or as an adjunct treatment with insulin or other oral hypoglycemic agents.
Mixtures: XIGDUO® XR 10MG/1000MG TABLETAS RECUBIERTAS DE LIBERACION PROLONGADA, XIGDUO® XR 10MG/1000MG TABLETAS RECUBIERTAS DE LIBERACION PROLONGADAProducts: Nra-dapagliflozin